EMEA-001397-PIP04-17-M01 - paediatric investigation plan
Ibrutinib
PIPHuman
Janssen-Cilag International N.V.
Tel. +32 1 464 1125
E-mail: JWeemer1@its.jnj.com
P/0421/2019: EMA decision of 6 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for ibrutinib (Imbruvica), (EMEA-001397-PIP04-17-M01)